COMMUNIQUÉS West-GlobeNewswire

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K
18/03/2025
SARASOTA, Fla., March 18, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced the [...]
HIV and Syphilis Testing Just Got Faster: bioLytical Launches the 1-Minute INSTI® Multiplex HIV-1/2 Syphilis Antibody Test in Australia
18/03/2025
The fastest rapid dual test for HIV and syphilis is now available in Australia, expanding access to reliable and accessible screening. A Major Step Forward in Infectious Disease Screening The INSTI® Multiplex HIV-1/2 [...]
Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System
18/03/2025
Increasing Accessibility for Flow Cytometry Applications in Emerging and Established Markets FREMONT, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Today, Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that it has added [...]
BioSyent Announces Grant of Restricted Share Units
18/03/2025
MISSISSAUGA, Ontario, March 18, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 56,767 Restricted Share Units “RSUs” to [...]
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
18/03/2025
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host [...]
Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
18/03/2025
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host [...]
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
18/03/2025
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Company expects to [...]
Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
18/03/2025
Significant progress in preclinical pipeline targeting KRAS-driven solid tumor cancers with systemic administration demonstrating robust anti-tumor and anti-metastasis activity in orthotopic mouse models; Recent funding [...]
Kalaris Announces Closing of Merger with AlloVir
18/03/2025
Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina [...]
Maravai Lifesciences Reports Fourth Quarter and Full Year 2024 Financial Results
18/03/2025
Schedules Conference Call for Thursday, March 20, 2025 SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services [...]
IR-MED CEO Issues Letter to Shareholders: Expanding Our Platform and Presenting New Clinical Data from Israel and the U.S.
18/03/2025
Rosh Pina, Israel, March 18, 2025 (GLOBE NEWSWIRE) -- IR-MED Inc. (“IR-MED” or the “Company”) (OTCQB: IRME), a developer of noninvasive, AI-driven spectrographic analysis technology addressing significant healthcare [...]
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025
18/03/2025
IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market [...]
Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
18/03/2025
Pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L metastatic breast cancer on track for top-line data in 2026 Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with [...]
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
18/03/2025
SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results. Fourth [...]
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
18/03/2025
RADNOR, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]
HealthEquity Reports Fiscal Year and Fourth Quarter Ended January 31, 2025 Financial Results
18/03/2025
Highlights of the fiscal year include: Revenue of $1.20 billion, an increase of 20% compared to $999.6 million in FY24. Net income of $96.7 million, an increase of 74% compared to $55.7 million in FY24, with non-GAAP [...]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/03/2025
SOUTH SAN FRANCISCO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 14, 2025 it granted stock options to purchase an aggregate of 58,631 shares of [...]
BioAegis Therapeutics to Highlight Lead Product Gelsolin’s Critical Role in Immune Function at Upcoming Conferences
18/03/2025
Phase 2 clinical trial will be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, Belgium on March 19, 2025. COO Valerie Ceva will present at MedInvest [...]
Antibe Announces Completion of Sale
18/03/2025
TORONTO, March 18, 2025 (GLOBE NEWSWIRE) -- Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) announced that, in connection with its previously announced receivership proceedings, the Company completed a [...]

Pages